A lower average cost did not establish that melatonin was more cost-effective than midazolam.
Study findings
The within-trial economic analysis focused on one hundred treated children, fifty per group, from the MAGIC study of preoperative anxiety. Average fourteen-day costs favored melatonin by approximately forty-six pounds, but uncertainty included costs in either direction. Procedure success and quality-adjusted-life-year differences were also uncertain. Bootstrap estimates occupied all four cost-effectiveness quadrants, so a single incremental ratio was not calculated.
What limits the conclusion
The parent trial closed early because recruitment was inadequate: 110 participants were recruited against a target of 624. Small subgroups and limited follow-up restricted the economic analysis. The clinical anxiety findings and the economic conclusion are separate questions. Local medicine prices, staffing and perioperative pathways also affect transferability.
Implications for case review
A resource-use opinion should retain both costs and clinical effects, together with their uncertainty. A cheaper bottle or lower sample mean is not enough to establish better value. This study illustrates how an under-recruited clinical trial can leave an economic comparison unresolved. It cannot determine the best premedication for an individual child or support a categorical purchasing claim without considering anxiety control, the local care setting and the limitations of the observed sample.
Source and related reading
Source: PMC12821929, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Pediatric Emergence-Agitation Comparison Also Changed Route of Premedication.
Leave a Reply